Patents and Licenses

OptiGen holds the exclusive license for these tests from Cornell Research Foundation, Inc.:
CEA/CH, US Patent No. 7462455; European Patent No. EP1652937

CSNB US Patent No. 6,201,114 and US Patent No. 6,428,958

prcd-PRA US Patent No. 5,804,388;  prcd-PRA Canadian Patent No. CA2306194; prcd-PRA UK Patent No. 2 341 926

prcd-PRA Mutation US Patent No. 7,312,037; Australian, Canadian and European Patents AU2005202704, CA2507927, EP1609876

prcd-PRA LD US Patent No. 7811761; Canadian and European Patents Pending No. 6256346.5

RD/OSD US, Australian, Canadian and European Patents Pending, No. AU2008293550, CA2698202, US2008293550 and EP8798766.5

OptiGen holds the exclusive license for CL testing in the U.S. and a non-exclusive license for other regions from the inventors at U. of New South Wales and the Border Collie Club of NSW, Australia, for this test. US Patent 7,723,034.

OptiGen holds the exclusive license for this test from the inventors at the Swedish University in Uppsala, Sweden:
CLAD Patent No. 6,210,897

OptiGen holds the exclusive U.S. and Canada license for this test from Merlogen, LLC:
FN Patent No. 7,285,388

OptiGen tests are provided pursuant to a license from Genetic Technologies Limited for their Non-Coding/Mapping Patents.